Bayer Data at ASCO 2019 Highlights Commitment to Evolving the Cancer Treatment Paradigm
Advertisement
- Data include new analyses on Vitrakvi® (larotrectinib), with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion: one on expanded data in pediatric patients and the other on patients with brain metastases or primary central nervous system tumors
